<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6649545</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">31353868</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">6649545</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1002/acn3.50798</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">ACN350798</article-id></all-ids><extracted-table><table-id>acn350798-tbl-0001</table-id><table-label>Table 1</table-label><table-caption>Patient characteristics.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="acn350798-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Patient</th><th align="left" rowspan="2" valign="top" colspan="1">Sex</th><th align="left" rowspan="2" valign="top" colspan="1">Age</th><th align="left" rowspan="2" valign="top" colspan="1">IgGNMDA receptor antibodies (CSF titer)</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Symptoms</th><th align="left" rowspan="2" valign="top" colspan="1">Duration of unconsciousness, day</th><th align="left" rowspan="2" valign="top" colspan="1">Treatment protocol</th><th align="left" rowspan="2" valign="top" colspan="1">Hospital stay month</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Paraneoplastic syndrome</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">mRS score</th><th align="left" rowspan="2" valign="top" colspan="1">AEDs at study time point</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Initial</th><th align="left" valign="top" rowspan="1" colspan="1">Total</th><th align="left" valign="top" rowspan="1" colspan="1">Tumor</th><th align="left" valign="top" rowspan="1" colspan="1">Resection</th><th align="left" valign="top" rowspan="1" colspan="1">Before treatment</th><th align="left" valign="top" rowspan="1" colspan="1">Study time point</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior, seizure</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition</td><td align="left" rowspan="1" colspan="1">15–20</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, cyclophosphamide</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">Topiramate 50 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior, dyskinesia</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition, autonomic instability</td><td align="left" rowspan="1" colspan="1">20–25</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, cyclophosphamide</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Seizure, LOC</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition, autonomic instability</td><td align="left" rowspan="1" colspan="1">25–30</td><td align="left" rowspan="1" colspan="1">IVIG, cyclophosphamide</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Dyskinesia, seizure</td><td align="left" rowspan="1" colspan="1">Dyskinesia, seizure, behavior, cognition</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, rituximab</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Oxcarbazepine 900 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition</td><td align="left" rowspan="1" colspan="1">10–15</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, cyclophosphamide</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior, cognition</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizures, behavior, cognition, autonomic instability</td><td align="left" rowspan="1" colspan="1">700+</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, plasmapheresis, IVIG, rituximab, cyclophosphamide</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">Mature cystic teratoma of left ovarian</td><td align="left" rowspan="1" colspan="1">yes</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizures, behavior, cognition</td><td align="left" rowspan="1" colspan="1">10–15</td><td align="left" rowspan="1" colspan="1">Cyclophosphamide</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior, seizure</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizures, behavior, cognition</td><td align="left" rowspan="1" colspan="1">20–25</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, rituximab, cyclophosphamide</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">Mature cystic teratoma of bilateral ovarian</td><td align="left" rowspan="1" colspan="1">yes</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior, dyskinesia</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizures, behavior, cognition</td><td align="left" rowspan="1" colspan="1">20–25</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, rituximab, cyclophosphamide</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior</td><td align="left" rowspan="1" colspan="1">LOC, behavior, cognition</td><td align="left" rowspan="1" colspan="1">8–10</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">1:10</td><td align="left" rowspan="1" colspan="1">Seizure, behavior</td><td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition</td><td align="left" rowspan="1" colspan="1">15–20</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">1:10</td><td align="left" rowspan="1" colspan="1">Dyskinesia, cognition</td><td align="left" rowspan="1" colspan="1">Dyskinesia, behavior, cognition</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">1:10</td><td align="left" rowspan="1" colspan="1">Seizure, behavior,</td><td align="left" rowspan="1" colspan="1">LOC, seizure, behavior, cognition, autonomic instability</td><td align="left" rowspan="1" colspan="1">20–25</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Seizure, behavior,</td><td align="left" rowspan="1" colspan="1">Seizure, behavior, cognition</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">Mature cystic teratoma of right ovarian</td><td align="left" rowspan="1" colspan="1">yes</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior, seizure</td><td align="left" rowspan="1" colspan="1">LOC, seizure, behavior, cognition</td><td align="left" rowspan="1" colspan="1">20–25</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">1:32</td><td align="left" rowspan="1" colspan="1">Behavior, seizure</td><td align="left" rowspan="1" colspan="1">Seizure, behavior, cognition</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">None</td></tr></tbody></table><table-wrap-foot><fn id="acn350798-note-0003"><p>CSF, cerebrospinal fluid; LOC, loss of consciousness; IVIG, intravenous human immunoglobulin; mRS, modified Rankin Score; AEDs, antiepileptic drugs; NA, not applicable.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Patient characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top">Patient</th><th align="left" rowspan="2" valign="top">Sex</th><th align="left" rowspan="2" valign="top">Age</th><th align="left" rowspan="2" valign="top">IgGNMDA receptor antibodies (CSF titer)</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top">Symptoms</th><th align="left" rowspan="2" valign="top">Duration of unconsciousness, day</th><th align="left" rowspan="2" valign="top">Treatment protocol</th><th align="left" rowspan="2" valign="top">Hospital stay month</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top">Paraneoplastic syndrome</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top">mRS score</th><th align="left" rowspan="2" valign="top">AEDs at study time point</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top">Initial</th><th align="left" valign="top">Total</th><th align="left" valign="top">Tumor</th><th align="left" valign="top">Resection</th><th align="left" valign="top">Before treatment</th><th align="left" valign="top">Study time point</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">F</td><td align="left">22</td><td align="left">1:32</td><td align="left">Behavior, seizure</td><td align="left">LOC, dyskinesia, seizure, behavior, cognition</td><td align="left">15–20</td><td align="left">High‐dose steroids, IVIG, cyclophosphamide</td><td align="left">1.1</td><td align="left">None</td><td align="left">/</td><td align="left">5</td><td align="left">0</td><td align="left">Topiramate 50 mg/day</td></tr><tr><td align="left">2</td><td align="left">M</td><td align="left">28</td><td align="left">1:32</td><td align="left">Behavior, dyskinesia</td><td align="left">LOC, dyskinesia, seizure, behavior, cognition, autonomic instability</td><td align="left">20–25</td><td align="left">High‐dose steroids, IVIG, cyclophosphamide</td><td align="left">1.2</td><td align="left">None</td><td align="left">/</td><td align="left">5</td><td align="left">1</td><td align="left">None</td></tr><tr><td align="left">3</td><td align="left">M</td><td align="left">31</td><td align="left">1:32</td><td align="left">Seizure, LOC</td><td align="left">LOC, dyskinesia, seizure, behavior, cognition, autonomic instability</td><td align="left">25–30</td><td align="left">IVIG, cyclophosphamide</td><td align="left">1.4</td><td align="left">None</td><td align="left">/</td><td align="left">5</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">4</td><td align="left">F</td><td align="left">15</td><td align="left">1:32</td><td align="left">Dyskinesia, seizure</td><td align="left">Dyskinesia, seizure, behavior, cognition</td><td align="left">NA</td><td align="left">High‐dose steroids, IVIG, rituximab</td><td align="left">1.2</td><td align="left">None</td><td align="left">/</td><td align="left">4</td><td align="left">1</td><td align="left">Oxcarbazepine 900 mg/day</td></tr><tr><td align="left">5</td><td align="left">F</td><td align="left">24</td><td align="left">1:32</td><td align="left">Behavior</td><td align="left">LOC, dyskinesia, seizure, behavior, cognition</td><td align="left">10–15</td><td align="left">High‐dose steroids, IVIG, cyclophosphamide</td><td align="left">1.2</td><td align="left">None</td><td align="left">/</td><td align="left">5</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">6</td><td align="left">F</td><td align="left">34</td><td align="left">1:32</td><td align="left">Behavior, cognition</td><td align="left">LOC, dyskinesia, seizures, behavior, cognition, autonomic instability</td><td align="left">700+</td><td align="left">High‐dose steroids, plasmapheresis, IVIG, rituximab, cyclophosphamide</td><td align="left">26</td><td align="left">Mature cystic teratoma of left ovarian</td><td align="left">yes</td><td align="left">5</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">7</td><td align="left">M</td><td align="left">22</td><td align="left">1:32</td><td align="left">Behavior</td><td align="left">LOC, dyskinesia, seizures, behavior, cognition</td><td align="left">10–15</td><td align="left">Cyclophosphamide</td><td align="left">0.8</td><td align="left">None</td><td align="left">/</td><td align="left">4</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">8</td><td align="left">F</td><td align="left">25</td><td align="left">1:32</td><td align="left">Behavior, seizure</td><td align="left">LOC, dyskinesia, seizures, behavior, cognition</td><td align="left">20–25</td><td align="left">High‐dose steroids, IVIG, rituximab, cyclophosphamide</td><td align="left">1.2</td><td align="left">Mature cystic teratoma of bilateral ovarian</td><td align="left">yes</td><td align="left">5</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">9</td><td align="left">F</td><td align="left">20</td><td align="left">1:32</td><td align="left">Behavior, dyskinesia</td><td align="left">LOC, dyskinesia, seizures, behavior, cognition</td><td align="left">20–25</td><td align="left">High‐dose steroids, IVIG, rituximab, cyclophosphamide</td><td align="left">1.3</td><td align="left">None</td><td align="left">/</td><td align="left">5</td><td align="left">2</td><td align="left">None</td></tr><tr><td align="left">10</td><td align="left">F</td><td align="left">30</td><td align="left">1:32</td><td align="left">Behavior</td><td align="left">LOC, behavior, cognition</td><td align="left">8–10</td><td align="left">High‐dose steroids, IVIG</td><td align="left">0.7</td><td align="left">None</td><td align="left">/</td><td align="left">4</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">11</td><td align="left">M</td><td align="left">49</td><td align="left">1:10</td><td align="left">Seizure, behavior</td><td align="left">LOC, dyskinesia, seizure, behavior, cognition</td><td align="left">15–20</td><td align="left">High‐dose steroids, IVIG</td><td align="left">1.2</td><td align="left">None</td><td align="left">/</td><td align="left">5</td><td align="left">1</td><td align="left">None</td></tr><tr><td align="left">12</td><td align="left">F</td><td align="left">34</td><td align="left">1:10</td><td align="left">Dyskinesia, cognition</td><td align="left">Dyskinesia, behavior, cognition</td><td align="left">NA</td><td align="left">High‐dose steroids, IVIG</td><td align="left">0.8</td><td align="left">None</td><td align="left">/</td><td align="left">4</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">13</td><td align="left">F</td><td align="left">42</td><td align="left">1:10</td><td align="left">Seizure, behavior,</td><td align="left">LOC, seizure, behavior, cognition, autonomic instability</td><td align="left">20–25</td><td align="left">High‐dose steroids, IVIG</td><td align="left">1.2</td><td align="left">None</td><td align="left">/</td><td align="left">5</td><td align="left">1</td><td align="left">None</td></tr><tr><td align="left">14</td><td align="left">F</td><td align="left">25</td><td align="left">1:32</td><td align="left">Seizure, behavior,</td><td align="left">Seizure, behavior, cognition</td><td align="left">NA</td><td align="left">High‐dose steroids, IVIG</td><td align="left">1.3</td><td align="left">Mature cystic teratoma of right ovarian</td><td align="left">yes</td><td align="left">5</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">15</td><td align="left">M</td><td align="left">22</td><td align="left">1:32</td><td align="left">Behavior, seizure</td><td align="left">LOC, seizure, behavior, cognition</td><td align="left">20–25</td><td align="left">High‐dose steroids, IVIG</td><td align="left">1.3</td><td align="left">None</td><td align="left">/</td><td align="left">4</td><td align="left">0</td><td align="left">None</td></tr><tr><td align="left">16</td><td align="left">F</td><td align="left">52</td><td align="left">1:32</td><td align="left">Behavior, seizure</td><td align="left">Seizure, behavior, cognition</td><td align="left">NA</td><td align="left">High‐dose steroids, IVIG</td><td align="left">1.2</td><td align="left">None</td><td align="left">/</td><td align="left">4</td><td align="left">1</td><td align="left">None</td></tr></tbody></table></div>CSF, cerebrospinal fluid; LOC, loss of consciousness; IVIG, intravenous human immunoglobulin; mRS, modified Rankin Score; AEDs, antiepileptic drugs; NA, not applicable.John Wiley &amp; Sons, Ltd</transformed-table></extracted-table><extracted-table><table-id>acn350798-tbl-0002</table-id><table-label>Table 2</table-label><table-caption>Demographic data and various putative predictive factors of the patients and healthy controls.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="acn350798-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Demographic data and various putative predictive factors of the patients and healthy controls.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Clinical variables</th><th align="left" valign="top" rowspan="1" colspan="1">HC</th><th align="left" valign="top" rowspan="1" colspan="1">First‐line only</th><th align="left" valign="top" rowspan="1" colspan="1">Second‐line</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>F</italic> (<italic>P</italic>)<xref ref-type="fn" rid="acn350798-note-0005">a</xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>χ</italic><sup>2</sup> (<italic>P</italic>)<xref ref-type="fn" rid="acn350798-note-0006">b</xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>t</italic> (<italic>P</italic>)<xref ref-type="fn" rid="acn350798-note-0007">c</xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>U</italic> (<italic>P</italic>)<xref ref-type="fn" rid="acn350798-note-0008">d</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (X ± SD, year)</td><td align="left" rowspan="1" colspan="1">30.27 ± 7.70</td><td align="left" rowspan="1" colspan="1">34.43 ± 10.85</td><td align="left" rowspan="1" colspan="1">25.33 ± 4.82</td><td align="left" rowspan="1" colspan="1">2.7 (0.084)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (X ± SD, year)</td><td align="left" rowspan="1" colspan="1">14.13 ± 2.07</td><td align="left" rowspan="1" colspan="1">11.14 ± 4.26</td><td align="left" rowspan="1" colspan="1">12.78 ± 3.63</td><td align="left" rowspan="1" colspan="1">2.23 (0.126)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (Male/Female)</td><td align="left" rowspan="1" colspan="1">5/10</td><td align="left" rowspan="1" colspan="1">2/5</td><td align="left" rowspan="1" colspan="1">3/6</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">0.056 (0.97)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">EEG abnormality (Absent/Present)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">2/5</td><td align="left" rowspan="1" colspan="1">3/6</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">0.042 (0.838)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">Seizures (Absent/Present)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">2/5</td><td align="left" rowspan="1" colspan="1">0/9</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">2.94 (0.086)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU treatment (Absent/Present)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">7/0</td><td align="left" rowspan="1" colspan="1">8/1</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">0.83 (0.362)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">Etiology (Idiopathic/Paraneoplastic)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">6/1</td><td align="left" rowspan="1" colspan="1">7/2</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">0.163 (0.687)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">Time of definite diagnosis (X ± SD, day)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">18.57 ± 7.61</td><td align="left" rowspan="1" colspan="1">16.89 ± 9.13</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">‐0.39 (0.70)</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">Time of follow‐up after initial discharge (median/IQR; range, month)</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">31/7–38; 6–47</td><td align="left" rowspan="1" colspan="1">9/6.5–11.5; 6–44</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">18.50 (0.167)</td></tr></tbody></table><table-wrap-foot><fn id="acn350798-note-0004"><p>EDB, extreme delta brush; IQR, interquartile range; HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy;</p></fn><fn id="acn350798-note-0005"><label>a</label><p>one‐way analysis of variance (ANOVA);</p></fn><fn id="acn350798-note-0006"><label>b</label><p>Chi‐square test;</p></fn><fn id="acn350798-note-0007"><label>c</label><p>Two‐sample <italic>t</italic>‐test;</p></fn><fn id="acn350798-note-0008"><label>d</label><p>Mann–Whitney <italic>U</italic> test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic data and various putative predictive factors of the patients and healthy controls.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top">Clinical variables</th><th align="left" valign="top">HC</th><th align="left" valign="top">First‐line only</th><th align="left" valign="top">Second‐line</th><th align="left" valign="top">F (P)???</th><th align="left" valign="top">χ2 (P)???</th><th align="left" valign="top">t (P)???</th><th align="left" valign="top">U (P)???</th></tr></thead><tbody><tr><td align="left">Age (X ± SD, year)</td><td align="left">30.27 ± 7.70</td><td align="left">34.43 ± 10.85</td><td align="left">25.33 ± 4.82</td><td align="left">2.7 (0.084)</td><td align="left">/</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">Education (X ± SD, year)</td><td align="left">14.13 ± 2.07</td><td align="left">11.14 ± 4.26</td><td align="left">12.78 ± 3.63</td><td align="left">2.23 (0.126)</td><td align="left">/</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">Sex (Male/Female)</td><td align="left">5/10</td><td align="left">2/5</td><td align="left">3/6</td><td align="left">/</td><td align="left">0.056 (0.97)</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">EEG abnormality (Absent/Present)</td><td align="left">/</td><td align="left">2/5</td><td align="left">3/6</td><td align="left">/</td><td align="left">0.042 (0.838)</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">Seizures (Absent/Present)</td><td align="left">/</td><td align="left">2/5</td><td align="left">0/9</td><td align="left">/</td><td align="left">2.94 (0.086)</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">ICU treatment (Absent/Present)</td><td align="left">/</td><td align="left">7/0</td><td align="left">8/1</td><td align="left">/</td><td align="left">0.83 (0.362)</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">Etiology (Idiopathic/Paraneoplastic)</td><td align="left">/</td><td align="left">6/1</td><td align="left">7/2</td><td align="left">/</td><td align="left">0.163 (0.687)</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">Time of definite diagnosis (X ± SD, day)</td><td align="left">/</td><td align="left">18.57 ± 7.61</td><td align="left">16.89 ± 9.13</td><td align="left">/</td><td align="left">/</td><td align="left">‐0.39 (0.70)</td><td align="left">/</td></tr><tr><td align="left">Time of follow‐up after initial discharge (median/IQR; range, month)</td><td align="left">/</td><td align="left">31/7–38; 6–47</td><td align="left">9/6.5–11.5; 6–44</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">18.50 (0.167)</td></tr></tbody></table></div>EDB, extreme delta brush; IQR, interquartile range; HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy;aone‐way analysis of variance (ANOVA);bChi‐square test;cTwo‐sample t‐test;dMann–Whitney U test.John Wiley &amp; Sons, Ltd</transformed-table></extracted-table><extracted-table><table-id>acn350798-tbl-0003</table-id><table-label>Table 3</table-label><table-caption>Summary of the neuropsychological test results among the patients and healthy controls.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="acn350798-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Summary of the neuropsychological test results among the patients and healthy controls.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Tests</th><th align="left" rowspan="2" valign="top" colspan="1">HC</th><th align="left" rowspan="2" valign="top" colspan="1">Second‐line</th><th align="left" rowspan="2" valign="top" colspan="1">First‐line only</th><th align="left" rowspan="2" valign="top" colspan="1"><italic>F</italic></th><th align="left" rowspan="2" valign="top" colspan="1"><italic>P</italic></th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Post hoc analysis (<italic>P</italic>)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">HC vs. second‐line</th><th align="left" valign="top" rowspan="1" colspan="1">HC vs. first‐line only</th><th align="left" valign="top" rowspan="1" colspan="1">Second‐line vs. first‐line only</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Stroop test (dot)</td><td align="left" rowspan="1" colspan="1">12.94 ± 2.64</td><td align="left" rowspan="1" colspan="1">14.05 ± 2.62</td><td align="left" rowspan="1" colspan="1">15.24 ± 2.36</td><td align="left" rowspan="1" colspan="1">1.81</td><td align="left" rowspan="1" colspan="1">0.183</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroop test (color word)</td><td align="left" rowspan="1" colspan="1">24.04 ± 4.80</td><td align="left" rowspan="1" colspan="1">30.91 ± 10.41</td><td align="left" rowspan="1" colspan="1">37.89 ± 16.36</td><td align="left" rowspan="1" colspan="1">3.35</td><td align="left" rowspan="1" colspan="1">0.080</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">SDMT</td><td align="left" rowspan="1" colspan="1">62.87 ± 7.80</td><td align="left" rowspan="1" colspan="1">48.78 ± 8.97</td><td align="left" rowspan="1" colspan="1">43.83 ± 13.66</td><td align="left" rowspan="1" colspan="1">11.25</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.331</td></tr><tr><td align="left" rowspan="1" colspan="1">Digit span test (forward)</td><td align="left" rowspan="1" colspan="1">9.40 ± 1.12</td><td align="left" rowspan="1" colspan="1">8.00 ± 1.32</td><td align="left" rowspan="1" colspan="1">8.00 ± 1.78</td><td align="left" rowspan="1" colspan="1">4.17</td><td align="left" rowspan="1" colspan="1">0.026</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="left" rowspan="1" colspan="1">0.038</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Digit span test (backward)</td><td align="left" rowspan="1" colspan="1">7.53 ± 1.46</td><td align="left" rowspan="1" colspan="1">5.33 ± 1.00</td><td align="left" rowspan="1" colspan="1">6.00 ± 2.00</td><td align="left" rowspan="1" colspan="1">6.93</td><td align="left" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.039</td><td align="left" rowspan="1" colspan="1">0.395</td></tr><tr><td align="left" rowspan="1" colspan="1">Semantic Fluency Test</td><td align="left" rowspan="1" colspan="1">21.87 ± 5.15</td><td align="left" rowspan="1" colspan="1">19.44 ± 4.77</td><td align="left" rowspan="1" colspan="1">15.33 ± 2.07</td><td align="left" rowspan="1" colspan="1">4.34</td><td align="left" rowspan="1" colspan="1">0.023</td><td align="left" rowspan="1" colspan="1">0.224</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">0.103</td></tr><tr><td align="left" rowspan="1" colspan="1">Block Design Test</td><td align="left" rowspan="1" colspan="1">40.60 ± 6.63</td><td align="left" rowspan="1" colspan="1">32.22 ± 6.57</td><td align="left" rowspan="1" colspan="1">31.67 ± 11.55</td><td align="left" rowspan="1" colspan="1">4.61</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">0.025</td><td align="left" rowspan="1" colspan="1">0.893</td></tr><tr><td align="left" rowspan="1" colspan="1">CAVLT (immediate memory following interference)</td><td align="left" rowspan="1" colspan="1">13.73 ± 1.10</td><td align="left" rowspan="1" colspan="1">13.56 ± 1.23</td><td align="left" rowspan="1" colspan="1">11.17 ± 1.94</td><td align="left" rowspan="1" colspan="1">8.49</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">CAVLT (delayed recall)</td><td align="left" rowspan="1" colspan="1">13.27 ± 1.71</td><td align="left" rowspan="1" colspan="1">12.78 ± 1.72</td><td align="left" rowspan="1" colspan="1">10.67 ± 1.51</td><td align="left" rowspan="1" colspan="1">5.23</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1">0.495</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">CAVLT (recognition)</td><td align="left" rowspan="1" colspan="1">14.80 ± 0.41</td><td align="left" rowspan="1" colspan="1">14.89 ± 0.33</td><td align="left" rowspan="1" colspan="1">13.50 ± 1.05</td><td align="left" rowspan="1" colspan="1">4.65</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">0.834</td><td align="left" rowspan="1" colspan="1">0.062</td><td align="left" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" rowspan="1" colspan="1">Self‐rating anxiety scale</td><td align="left" rowspan="1" colspan="1">23.47 ± 3.04</td><td align="left" rowspan="1" colspan="1">25.11 ± 6.43</td><td align="left" rowspan="1" colspan="1">26.33 ± 5.96</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0.493</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">Self‐rating depression scale</td><td align="left" rowspan="1" colspan="1">23.53 ± 3.83</td><td align="left" rowspan="1" colspan="1">26.89 ± 7.66</td><td align="left" rowspan="1" colspan="1">25.33 ± 5.68</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">0.456</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td><td align="left" rowspan="1" colspan="1">/</td></tr></tbody></table><table-wrap-foot><fn id="acn350798-note-0009"><p>SDMT, symbol‐digit modalities test; CAVLT, Chinese auditory verbal learning test; HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Summary of the neuropsychological test results among the patients and healthy controls.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><col style="border-right:solid 1px #000000"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top">Tests</th><th align="left" rowspan="2" valign="top">HC</th><th align="left" rowspan="2" valign="top">Second‐line</th><th align="left" rowspan="2" valign="top">First‐line only</th><th align="left" rowspan="2" valign="top">F</th><th align="left" rowspan="2" valign="top">P</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top">Post hoc analysis (P)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top">HC vs. second‐line</th><th align="left" valign="top">HC vs. first‐line only</th><th align="left" valign="top">Second‐line vs. first‐line only</th></tr></thead><tbody><tr><td align="left">Stroop test (dot)</td><td align="left">12.94 ± 2.64</td><td align="left">14.05 ± 2.62</td><td align="left">15.24 ± 2.36</td><td align="left">1.81</td><td align="left">0.183</td><td align="left">/</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">Stroop test (color word)</td><td align="left">24.04 ± 4.80</td><td align="left">30.91 ± 10.41</td><td align="left">37.89 ± 16.36</td><td align="left">3.35</td><td align="left">0.080</td><td align="left">/</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">SDMT</td><td align="left">62.87 ± 7.80</td><td align="left">48.78 ± 8.97</td><td align="left">43.83 ± 13.66</td><td align="left">11.25</td><td align="left">0.000</td><td align="left">0.002</td><td align="left">0.000</td><td align="left">0.331</td></tr><tr><td align="left">Digit span test (forward)</td><td align="left">9.40 ± 1.12</td><td align="left">8.00 ± 1.32</td><td align="left">8.00 ± 1.78</td><td align="left">4.17</td><td align="left">0.026</td><td align="left">0.019</td><td align="left">0.038</td><td align="left">1.000</td></tr><tr><td align="left">Digit span test (backward)</td><td align="left">7.53 ± 1.46</td><td align="left">5.33 ± 1.00</td><td align="left">6.00 ± 2.00</td><td align="left">6.93</td><td align="left">0.004</td><td align="left">0.001</td><td align="left">0.039</td><td align="left">0.395</td></tr><tr><td align="left">Semantic Fluency Test</td><td align="left">21.87 ± 5.15</td><td align="left">19.44 ± 4.77</td><td align="left">15.33 ± 2.07</td><td align="left">4.34</td><td align="left">0.023</td><td align="left">0.224</td><td align="left">0.007</td><td align="left">0.103</td></tr><tr><td align="left">Block Design Test</td><td align="left">40.60 ± 6.63</td><td align="left">32.22 ± 6.57</td><td align="left">31.67 ± 11.55</td><td align="left">4.61</td><td align="left">0.019</td><td align="left">0.016</td><td align="left">0.025</td><td align="left">0.893</td></tr><tr><td align="left">CAVLT (immediate memory following interference)</td><td align="left">13.73 ± 1.10</td><td align="left">13.56 ± 1.23</td><td align="left">11.17 ± 1.94</td><td align="left">8.49</td><td align="left">0.001</td><td align="left">0.754</td><td align="left">0.000</td><td align="left">0.002</td></tr><tr><td align="left">CAVLT (delayed recall)</td><td align="left">13.27 ± 1.71</td><td align="left">12.78 ± 1.72</td><td align="left">10.67 ± 1.51</td><td align="left">5.23</td><td align="left">0.012</td><td align="left">0.495</td><td align="left">0.003</td><td align="left">0.024</td></tr><tr><td align="left">CAVLT (recognition)</td><td align="left">14.80 ± 0.41</td><td align="left">14.89 ± 0.33</td><td align="left">13.50 ± 1.05</td><td align="left">4.65</td><td align="left">0.034</td><td align="left">0.834</td><td align="left">0.062</td><td align="left">0.049</td></tr><tr><td align="left">Self‐rating anxiety scale</td><td align="left">23.47 ± 3.04</td><td align="left">25.11 ± 6.43</td><td align="left">26.33 ± 5.96</td><td align="left">0.76</td><td align="left">0.493</td><td align="left">/</td><td align="left">/</td><td align="left">/</td></tr><tr><td align="left">Self‐rating depression scale</td><td align="left">23.53 ± 3.83</td><td align="left">26.89 ± 7.66</td><td align="left">25.33 ± 5.68</td><td align="left">0.85</td><td align="left">0.456</td><td align="left">/</td><td align="left">/</td><td align="left">/</td></tr></tbody></table></div>SDMT, symbol‐digit modalities test; CAVLT, Chinese auditory verbal learning test; HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy.John Wiley &amp; Sons, Ltd</transformed-table></extracted-table></extracted-tables-set>